Oncotelic Therapeutics, Inc. (OTLC) said Chief Business Officer Saran Saund presented at the 22nd Drug Discovery Strategic Summit on October 22, 2026. The presentation title referenced partitioning 29 million PubMed abstracts by disease. For liver cancer research, the company described combining literature analysis with gene-expression and survival analyses to identify a four-gene mTOR-related signature associated with patient outcomes and a candidate hepatocellular carcinoma population. The presentation also outlined a proposed expansion of the Partitioned Literature Aggregation framework through autonomous AI agents and a planned research environment targeting 100 billion protein-related vectors to support drug discovery across multiple disease areas.
Oncotelic Therapeutics, Inc. representatives presented information about the PDAOAI platform and hepatocellular carcinoma research at Drug Discovery 2026 in Burlingame, California, on October 7 and 8, 2026. Product Manager Scott Myers described a workflow that searches and aggregates evidence across approximately 29 million PubMed abstracts, analyzing defined literature groups separately before combining findings.
Chief Business Officer Saran Saund presented a four-gene mTOR-related signature associated with overall survival in an exploratory discovery analysis and an independent Japanese patient cohort. The retrospective findings do not establish that the signature predicts treatment benefit from everolimus, Sapu003, or other mTOR-directed therapies. The presentations also described BIO REBOOT, which invites proposed therapeutic research projects; selected projects may qualify for startup funding and development support, subject to scientific review, available resources, and agreed terms.
Oncotelic Therapeutics, Inc. reported total assets of $394.8 million at June 30 2026, driven largely by a Level 3 fair value investment in its GMP Bio joint venture of $388.0 million and a Lunai Bioworks equity investment of $1.4 million.
For Q2 2026, the company generated $250,000 of service revenue and an operating loss of $843,565, but posted net income attributable to Oncotelic of $388,147 due mainly to a $1.1 million gain on derecognition of a non‑financial asset and a $300,000 gain on its Lunai investment. For the six months, it recorded a net loss of $1.9 million and operating cash outflow of $434,440, funded by $531,597 of net financing inflows including $500,000 in new convertible debt.
Oncotelic discloses negative working capital of about $16.4 million, total liabilities of $131.3 million (including a $111.6 million deferred tax liability), and substantial convertible and short‑term debt. Management states that recurring losses, limited recent fundraising and liquidity shortfall raise substantial doubt about its ability to continue as a going concern without additional capital.
Oncotelic Therapeutics, Inc. entered into a Securities Purchase Agreement with Pacific Pier Capital II, LP and issued a 2026 Pacific Pier Note 2, a convertible promissory note with aggregate gross principal of $178,410. The note bears 12% annual interest, includes a 12% original issue discount, and matures on the earlier of one year from the agreement date, acceleration upon an Event of Default, or full prepayment.
The note is convertible into common stock at the lesser of a fixed $0.06 per share Conversion Price or 85% of the lowest traded price over the ten trading days before conversion, with adjustment for certain corporate events. Oncotelic also issued 500,000 commitment shares to Pacific Pier. Prepayment is permitted at any time prior to six months from the note date with notice, and upon an Event of Default the amount becomes immediately due in cash with default interest of 16% per annum. The issuance relies on a Section 4(a)(2) Securities Act exemption.
Fein Seymour Howard reported acquisition or exercise transactions in this Form 4 filing.
Oncotelic Therapeutics, Inc. granted its CRO/CMO, Seymour Howard Fein, 250 restricted stock units on July 10, 2026. Each RSU will settle into one share of Series A Convertible Preferred Stock, and each preferred share is convertible into 1,000 common shares, contingent on performance and time-based vesting. Vesting requires an uplisting of the common stock to a national securities exchange by June 30, 2027 (or a later Board-approved date) and six months of continued service after the uplisting.
Oncotelic Therapeutics, Inc., a Delaware biotechnology company with no revenues, filed a Form D for an exempt offering under Rule 506(b). The company reports a Total Amount Sold of $711,840 USD in equity securities, including options, warrants and securities issuable upon exercise.
The securities consist of RSUs convertible into Series A preferred shares and then common stock, granted to directors, officers, employees and advisors as compensation for services. These RSUs are contingent on achieving specified corporate milestones. The notice indicates $0 USD remaining to be sold and finder’s fees of $0 USD. CEO Vuong Trieu signed the notice on behalf of the issuer.
KING STEVEN W reported acquisition or exercise transactions in this Form 4 filing.
Oncotelic Therapeutics granted director Steven W. King 250 restricted stock units (RSUs) on July 10, 2026 at $0.00 per unit. Each RSU is subject to performance and time-based vesting and represents a contingent right to one share of Series A Convertible Preferred Stock, with each such share convertible into 1,000 common shares. The RSUs vest only if the company uplists its common stock to a national securities exchange on or before June 30, 2027 (or a later Board-approved date) and he remains in service for six months after any such uplisting; following this grant he holds 250 RSUs directly.
Oncotelic Therapeutics, Inc. reports that on July 13, 2026 it delivered a corporate presentation to its employees, directors, officers and advisors. The presentation, referred to as the “Corporate Presentation,” is provided as Exhibit 99.1 to the current report.
The company states that the information furnished under Section 8.01, including Exhibit 99.1, is being furnished rather than filed for purposes of Section 18 of the Securities Exchange Act of 1934. It also clarifies that this information is not incorporated by reference into any Securities Act or Exchange Act filing, except where specifically referenced. The report is signed on behalf of the company by Vuong Trieu, Ph.D., its Chief Executive Officer.
Oncotelic Therapeutics, Inc. approved equity incentives for directors, officers, employees and advisors by granting an aggregate 17,796 restricted stock units (RSUs) under Restricted Stock Unit Award Agreements. Each RSU represents a contingent right to receive one share of Series A Convertible Preferred Stock, which is convertible into 1,000 shares of common stock.
The RSUs vest only if the company’s common stock is uplisted to a national stock exchange on or before June 30, 2027, or a later date if extended by the board, and the recipient continues service for six months after the uplisting. Otherwise, the RSUs automatically expire and are forfeited. Grants include 2,000 RSUs to CEO Vuong Trieu and 1,500 RSUs each to several senior executives. The awards are granted at no cost to recipients and rely on the private-offering exemption in Section 4(a)(2) of the Securities Act.
MAIDA ANTHONY E III reported acquisition or exercise transactions in this Form 4 filing.
Oncotelic Therapeutics, Inc. reported that director and Chief Medical Officer – Translational Medicine Anthony E. Maida III received a grant of 1,500 restricted stock units (RSUs) on July 10, 2026 at no cost. Each RSU settles into one share of Series A Convertible Preferred Stock, which is convertible into 1,000 shares of common stock. The RSUs are subject to performance and time-based vesting, becoming eligible upon an uplisting of the company’s common stock to a national securities exchange on or before June 30, 2027 (or a later Board-approved date) and the executive’s continued service for six months following the uplisting.